0001125345-21-000054.txt : 20210419 0001125345-21-000054.hdr.sgml : 20210419 20210419183741 ACCESSION NUMBER: 0001125345-21-000054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210415 FILED AS OF DATE: 20210419 DATE AS OF CHANGE: 20210419 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spitznagel Thomas CENTRAL INDEX KEY: 0001675464 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 21835761 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 4 1 wf-form4_161887184277337.xml FORM 4 X0306 4 2021-04-15 0 0001125345 MACROGENICS INC MGNX 0001675464 Spitznagel Thomas 9704 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 0 1 0 0 Sr VP, BPD & Manufacturing Common Stock 2021-04-15 4 M 0 5000 7.51 A 5000 D Common Stock 2021-04-15 4 S 0 5000 30.91 D 0 D Employee stock option (right to buy) 7.51 2021-04-15 4 M 0 5000 7.51 D 2014-03-18 2023-09-17 Common Stock 5000.0 42147 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2021. This transaction was executed in multiple trades at prices ranging from $30.71 to $31.20. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 12.5% of the shares underlying the grant become (or became) exercisable on the date reflected and an additional 6.25% of the shares underlying the grant become (or became) exercisable on the first day of each three-month period thereafter. /s/ Lynn Cilinski, Attorney-in-Fact 2021-04-19